11 Einträge gefunden

1. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis

   1. Gordon, K B
   2. Lebwohl, M
   3. Papp, K A
   4. Bachelez, H
   5. Wu, J J
   6. Langley, R G
   7. Blauvelt, A

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

   1. Reich, K
   2. Gordon, K B
   3. Strober, B
   4. Langley, R G
   5. Miller, M
   6. Yang, Y-W
   7. Shen, Y-K

   2022 - Forschungsinformationssystem des UKE
3. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

   1. Warren, R B
   2. Lebwohl, M
   3. Sofen, H
   4. Piguet, V
   5. Augustin, M
   6. Brock, F
   7. C Arendt,

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

   1. Blauvelt, A
   2. Paul, C
   3. van de Kerkhof, P
   4. Warren, R B
   5. Gottlieb, A B
   6. Langley, R G
   7. Brock, F

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)

   1. Gordon, K B
   2. Warren, R B
   3. Gottlieb, A B
   4. Blauvelt, A
   5. Thaçi, D
   6. Leonardi, C
   7. Poulin, Y

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

   1. Kimball, A B
   2. Kerbusch, T
   3. van Aarle, F
   4. Kulkarni, P
   5. Li, Q
   6. Blauvelt, A
   7. Papp, K A

   2020 - Forschungsinformationssystem des UKE
7. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

   1. Blauvelt, A
   2. Papp, K
   3. Gottlieb, A
   4. Jarell, A
   5. Reich, K
   6. Maari, C
   7. Gordon, K B

   2020 - Forschungsinformationssystem des UKE
8. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

   1. Kimball, A B
   2. Papp, K A
   3. Reich, K
   4. Gooderham, M
   5. Li, Q
   6. Cichanowitz, N
   7. La Rosa, C

   2020 - Forschungsinformationssystem des UKE
9. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing Spondylitis: integrated pooled clinical trial and post-marketing surveillance data

   1. Deodhar, A
   2. Mease, P J
   3. McInnes, I B
   4. Baraliakos, X
   5. Reich, K
   6. Blauvelt, A
   7. Leonardi, C

   2019 - Forschungsinformationssystem des UKE - frei zugänglich
10. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials

    1. Blauvelt, A
    2. Sofen, H
    3. Papp, K
    4. Gooderham, M
    5. Tyring, S
    6. Zhao, Y
    7. Lowry, S

    2019 - Forschungsinformationssystem des UKE
11. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

    1. Reich, K
    2. Blauvelt, A
    3. Armstrong, A
    4. Langley, R G
    5. de Vera, A
    6. Kolbinger, F
    7. Spindeldreher, S

    2019 - Forschungsinformationssystem des UKE